Elixir Associates

?? Astrocyte Transplantation: Pioneering Brain Repair! Astrocyte transplantation is breaking new ground in the treatment of neurodegenerative diseases, brain injuries, and disorders like ALS and Huntington's. This innovative therapy leverages the regenerative capabilities of these vital support cells to restore brain function. ?? Key Insights?? ??Disease Modulation: Astrocytes influence neurological conditions, such as ALS, where disease symptoms emerge when only astrocytes carry mutations. ??Integration Success: Transplanted astrocytes survive up to a year and integrate with native cells, supporting synaptic function and neuroplasticity ??Personalized Approach: Donor cell type and timing significantly impact therapy effectiveness ??As studies advance, astrocyte transplantation is moving closer to clinical applications, offering hope for transformative treatments. Learn more about the science behind this innovation here. #Neuroscience #BrainHealth #Astrocytes #Innovation #RegenerativeMedicine #Biotech #Cellbiology

Exciting news as Forte Biosciences have raised $53M in an oversubscribed equity financing to advance their clinical-stage development. This investment will push forward research on FB-102, an anti-CD122 monoclonal antibody therapeutic candidate ?? - Lead investors: OrbiMed, Janus Henderson Investors, and Tybourne Capital Management ?? - Study on healthy volunteers: Completed ? - Trials for celiac disease: Underway, with early results expected by Q2 2025 ?? - Plans to investigate other autoimmune conditions in 2025 ?? I’ll be keeping a close eye on Forte Biosciences’ R&D update on December 3rd—looking forward to gaining more insights into this exciting development! ?? Great work Forte Biosciences Team Chris Roenfeldt, PMP, Paul Wagner #ForteBiosciences #Biotech #Funding #TybourneCapitalManagement #OrbiMed #HealthcareInnovation #LifeScienceNews #ClinicalResearch #AutoimmuneDisease #ElixirAssociates https://lnkd.in/e5FUKwMs

Valora Therapeutics, Inc. have successfully launched with a $30 Million funding to redefine #Immunotherapy?. ?? ?? Their #AbLec platform which is a novel approach to #Immunotherapy was founded by groundbreaking research from Carolyn Bertozzi & Jessica Stark.?? ? Miguel Garcia-Guzman, Ph.D. - (Chief Executive Officer) ? Jerry Fong, Ph.D. - (Co-founder & Senior Director) ? Barbara Visentin - (Co-founder & Director) Huge congratulations to the whole Valora Therapeutics, Inc. family from everyone at Elixir Associates. ???? #Elixir #Congratulations #Biotech #News #Pharma #Financing #ClinicalDevelopment #Immunotherapy #Glycoimmunology #SanDiego

Exciting Development in Dry Eye Disease Treatment ?? Great news for the clinical research community! The FDA has accepted Aldeyra Therapeutics' resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational candidate for dry eye disease treatment. This marks a significant milestone for both Aldeyra and their partnering company, AbbVie. The expanded agreement now provides Aldeyra with $100 million upfront, with potential for an additional $300 million in regulatory and commercial milestone payments upon FDA approval. The agreement ensures both companies' commitment to accelerating the availability of this novel therapy. This collaboration could bring much-needed relief to those suffering from dry eye symptoms. With the FDA assigning a PDUFA date of April 2, 2025, both Aldeyra and AbbVie are set to initiate pre-commercial activities. This is an exciting time for advancements in ocular health, and I'm keen to see the positive impact this treatment may have on patients' lives. #ClinicalResearch #DryEyeDisease #Biotechnology #Pharmaceuticals #HealthcareInnovation

The ACR Convergence 2024 brought exciting updates on Lupus Nephritis treatments, focusing on preserving kidney function. Highlights include recommending a triple immunosuppression regimen as first-line therapy, featuring LUPKYNIS (voclosporin) for 3-5 years ?? Interesting features are a rapid steroid taper to <5 mg/day within 6 months and targeting proteinuria <0.5g/g UPCR by 12 months. The Phase 3 AURORA 1 study showed patients using LUPKYNIS with MMF and low-dose glucocorticoids had better renal response than those on MMF and glucocorticoids alone which is very positive ?? Excited to continue following this super journey! ?? Great work Aurinia Pharmaceuticals Inc. Gregory Keenan #AuriniaPharmaceuticals #LupusNephritis #SLE?#ACR2024 #KidneyHealth #AutoImmuneDisease #ClinicalResearch #LifeScienceNews #ElixirAssociates #StaffingPartner https://lnkd.in/eJEnj8Hj

Thanksgiving & Christmas are both just around the corner.... I hope everyone is excited to spend time with their loved ones. ?? Over the last 2 years since starting Elixir Associates, I have learned that being a good human being with a big heart is everything in life. Try to be the reason that people smile when they encounter you... be kind & be caring. ?? Along this journey we call life, don't let anyone ever tell you that you can't achieve something... set yourself goals & dreams... work hard to make them a reality. ?? From time to time you have to put yourself first but don't be selfish enough to forget about your family, friends & people you care about. Always give back to those in need & never ever forget who you are & where you come from... stay grounded & stay humble. (Don't forget to laugh... laughter is the best remedy to life) ?? #Elixir #PositiveMindset #BeKind #HelpEachother

C Ray Therapeutics has secured over $100 million in Series A+ funding, aiming to advance their radiopharmaceutical technology. Backed by Shenzhen Capital Group, Tailong Capital, Hillhouse's GL Ventures, and 3SBio, this funding represents a significant step forward for the company. Founded in 2021 in Chengdu, C Ray Therapeutics is fast becoming a leader in the field of radiopharmaceuticals, which use radioactive isotopes for diagnostics and treatment. The investment will help enhance their RDC drug screening capabilities and accelerate clinical trials. With a state-of-the-art Class A production base and 13 cGMP-standard workshops, all compliant with FDA, NMPA, and EMA regulations, the future looks promising for C Ray and the patients they serve. #Radiopharma #Healthcare #Innovation

Last week Bristol Myers Squibb showcased promising results of their CD19-directed CAR-T cell therapy, BMS-986353. This therapy has shown sustained clinical responses in patients with systemic lupus erythematosus (SLE) and has the potential to reset the immune system ?? BMS shared their findings at ACR Convergence 2024, revealing complete peripheral B-cell depletion in all evaluable SLE patients. Especially B cells, as they returned mainly as na?ve cells within three months. This data suggests a large drop in disease activity and symptoms, with patients recording improved quality of life metrics. Despite grade 3 or 4 adverse events, including neutropenia and a case of ICANS, the benefits observed are remarkable. #CAR-TTherapy #SLE #ClinicalResearch #BristolMyersSquibb #ClinicalTrials #LifeScience #ACRConvergence2024 #ElixirAssociates #StaffingPartner

Exciting Development in Heart Health Care ?? The FDA has recently granted clearance to Omron Healthcare's innovative wearable device, adding a revolutionary feature to its at-home blood pressure cuffs. This device can now screen for atrial fibrillation (afib) using AI-powered software, even without relying on electrical signals. ???? Afib detection can be a game-changer in preventing strokes and heart attacks, especially as it's often under-diagnosed. Omron's new technology achieves an impressive 95% sensitivity and 98% specificity, according to a recent clinical trial published in the Heart Rhythm Journal. This advancement underscores the critical role of regular health monitoring in managing hypertension and afib, which affects many U.S. adults. #HealthcareInnovation #AIinMedicine #HeartHealth

Wonderful news released yesterday, as Adaptimmune Therapeutics are back in the spotlight with their game-changing cell therapy, lete-cel. In a pivotal phase 2 trial, 42% of patients with advanced sarcoma showed a positive response ?? In a study involving 64 patients with advanced synovial sarcoma or MRCLS, clinical responses were reported in 27 patients, including six complete responses and twenty-one partial responses. These results are clearly an improvement from earlier reports this year. A leading oncologist, expressed optimism about these results, suggesting they could offer new therapeutic options and better outcomes for young patients facing these challenging diagnoses. Adaptimmune plans to promote these findings at an upcoming oncology meeting and proceed with an FDA submission next year - watch this space! Well done to the Team at Adaptimmune Adrian (Ad) Rawcliffe???? #CancerTreatment #Oncology #ClinicalTrials #InnovationInHealth #AdaptimmuneTherapeutics #ClinicalResearch #LifeScience #ElixirAssociates https://lnkd.in/eiKwXQhT